R&D channel feed

With first hu­man da­ta, long-strug­gling Si­lence Ther­a­peu­tics leaps in­to next big car­dio­vas­cu­lar race

4 years ago

Tak­ing on Big Phar­ma-sized in­di­ca­tions, tiny biotech claims ear­ly win in fat loss. Will it trans­late to di­a­betes, NASH and be­yond?

4 years ago

Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try in 2022? Nom­i­nate them for End­points' spe­cial re­port

4 years ago
People

An­a­lysts ques­tion Karyophar­m's PhI­II en­dome­tri­al can­cer da­ta as biotech will charge ahead to FDA

4 years ago

'Very over sol­d': Biotech brags about PhII Alzheimer's da­ta, but ex­perts are un­der­whelmed

4 years ago

AD­Cs in the pipeline: FDA spells out clin­i­cal phar­ma­col­o­gy musts for spon­sors

4 years ago
FDA+

With de­ci­sion loom­ing on J&J, Leg­end's CAR-T, an­a­lyst sees a new cham­pi­on emerg­ing in boom­ing BC­MA space

4 years ago

How re­searchers can get a han­dle on the mon­key short­age for tox stud­ies: FDA ex­plains

4 years ago
FDA+

Bris­tol My­er­s' Caforio: CELMoDs have po­ten­tial to re­place Revlim­id and Po­m­a­lyst as block­busters start to lose ex­clu­siv­i­ty

4 years ago
Pharma

Re­gen­eron looks to George Yan­copoulos' R&D arm — and part­ners — in hunt for its next big cash cows

4 years ago
Pharma

Pfiz­er lands on For­tune’s most ad­mired list, edg­ing out Dis­ney, Google and Star­bucks in an­nu­al rep­u­ta­tion rank­ing

4 years ago

Van­da's gas­tric drug flops in late-stage test, crash­ing the biotech's stock

4 years ago

Watch out, As­traZeneca: UCB un­corks late-stage suc­cess for $2.1B Soliris ri­val

4 years ago

Bay­er bails on chron­ic cough drug from Evotec, putting the ki­bosh on lead med in mul­ti-tar­get col­lab­o­ra­tion

4 years ago
Deals

An­oth­er mi­cro­cap biotech plots ma­jor job cuts as in­dus­try sharp­ens its axe amid slow­down

4 years ago
People

'We need to do more': Mer­ck CEO Rob Davis high­lights M&A, deals strat­e­gy ahead of '28 Keytru­da patent cliff

4 years ago

Eli Lil­ly hits pause on Aduhelm ri­val do­nanemab as ex­ecs fret about Medicare's skep­ti­cal stance on Alzheimer's drug class

4 years ago
Pharma

As­traZeneca dumps off a mid-stage PAD hope­ful, sound­ing re­treat from a packed mar­ket

4 years ago
Deals

Macro­Gen­ics ear­marks $580M for ADC tech; Do­mainex, non­prof­it team up on Parkin­son's pro­gram

4 years ago
News Briefing

J&J takes a $610M hit as top PhI­II prospect goes up in flames af­ter atopic der­mati­tis study fails

4 years ago

Ab­b­Vie's Gon­za­lez: Skyrizi and Rin­voq to be­come Hu­mi­ra 2.0 — while adding an in­di­ca­tion for atopic der­mati­tis

4 years ago
Pharma

PhRMA goes on the of­fen­sive, at­tack­ing the WHO and putting the EU, UK, Aus­tralia and oth­ers on no­tice

4 years ago
Pharma

Carl June: ‘We can now con­clude that CAR-T cells can ac­tu­al­ly cure pa­tients’

4 years ago
Discovery

A win in Rett syn­drome? Not so fast — biotech shares slide amid con­cerns of last-minute tri­al changes

4 years ago
First page Previous page 147148149150151152153 Next page Last page
A service from the Financial Times